GGrantIndex
← Leaderboards

Macus T Kuo

University Of Texas Md Anderson Can Ctr

$7,802,009
Attributed
$7,802,009
Total exposure
6
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $667.2K · FY200514
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14

Funding mix

By agency

NIH$7,802,009 · 6

By mechanism

R01$7,802,009 · 6

Top collaborators

No co-investigators on record.

Most similar at University Of Texas Md Anderson Can Ctr

Same institution · by research overlap

Others in their field

Top investigators on “Drug Resistance

Research focus

Drug ResistanceCellsGene ExpressionRegulationMalignant NeoplasmsUp-Regulation (Physiology)ChemotherapyTumorBaseCell LineStagingProteinsMolecularLearningMultidrug ResistanceHomeostasisAnalogIn VivoMolecular ProfilingCopperCytotoxicAntitumor AgentClinical TrialsDna Microarray Chip

Grant awards (29)

Improving the Efficacy of Cisplatin-Based Cancer Chemotherapy$308,475
R01 · FY2014 · CA · contact PI
Improving the Efficacy of Cisplatin-Based Cancer Chemotherapy$298,935
R01 · FY2013 · CA · contact PI
Mechanism of Resistance to Arginine Deiminase Therapy in Advance Melanoma$290,165
R01 · FY2013 · CA · contact PI
Improving the Efficacy of Cisplatin-Based Cancer Chemotherapy$318,015
R01 · FY2012 · CA · contact PI
Mechanism of Resistance to Arginine Deiminase Therapy in Advance Melanoma$311,230
R01 · FY2012 · CA · contact PI
Improving the Efficacy of Cisplatin-Based Cancer Chemotherapy$318,015
R01 · FY2011 · CA · contact PI
Mechanism of Resistance to Arginine Deiminase Therapy in Advance Melanoma$313,841
R01 · FY2011 · CA · contact PI
Mechanism of Resistance to Arginine Deiminase Therapy in Advance Melanoma$339,391
R01 · FY2010 · CA · contact PI
Improving the Efficacy of Cisplatin-Based Cancer Chemotherapy$327,850
R01 · FY2010 · CA · contact PI
Redox Regulation of Multidrug Resistance Gene Expression$223,231
R01 · FY2009 · CA · contact PI
Genomic Instability and Evolution of Drug Resistance$293,510
R01 · FY2008 · CA · contact PI
Redox Regulation of Multidrug Resistance Gene Expression$223,231
R01 · FY2008 · CA · contact PI
Genomic Instability and Evolution of Drug Resistance$293,510
R01 · FY2007 · CA · contact PI
Redox Regulation of Multidrug Resistance Gene Expression$223,231
R01 · FY2007 · CA · contact PI
Genomic Instability and Evolution of Drug Resistance$272,048
R01 · FY2006 · CA · contact PI
Redox Regulation of Multidrug Resistance Gene Expression$229,898
R01 · FY2006 · CA · contact PI
Genomic Instability and Evolution of Drug Resistance$278,595
R01 · FY2005 · CA
Targeted Prodrug Therapy of Liver Cancers$268,780
R01 · FY2005 · CA
Regulation of MDR Gene Expression in Liver Cancers$280,125
R01 · FY2004 · CA
Genomic Instability and Evolution of Drug Resistance$278,595
R01 · FY2004 · CA
Targeted Prodrug Therapy of Liver Cancers$268,780
R01 · FY2004 · CA
Regulation of MDR Gene Expression in Liver Cancers$280,125
R01 · FY2003 · CA
Targeted Prodrug Therapy of Liver Cancers$268,780
R01 · FY2003 · CA
Regulation of MDR Gene Expression in Liver Cancers$280,125
R01 · FY2002 · CA
Targeted Prodrug Therapy of Liver Cancers$268,780
R01 · FY2002 · CA
Regulation of MDR Gene Expression in Liver Cancers$280,125
R01 · FY2001 · CA
REDOX REGULATION OF MULTIDRUG RESISTANCE GENE EXPESSION$214,698
R01 · FY2001 · CA
REGULATION OF MDR GENE EXPRESSION IN LIVER CANCERS$41,480
R01 · FY2001 · CA
REDOX REGULATION OF MULTIDRUG RESISTANCE GENE EXPESSION$208,445
R01 · FY2000 · CA